Waldenström macroglobulinaemia
Haematology · 2021–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| zanubrutinib Treatment of Waldenström macroglobulinaemia in treatment-naïve patients unsuitable for chemo-immunotherapy (defined by CIRS ≥6) and relapsed/refractory… | Mar 2022 | Recommended with restriction | 14 individuals Lymphoma Foundation · Leukaemia Foundation · Rare Cancers Australia |
| zanubrutinib Treatment of adult patients with Waldenström macroglobulinaemia (WM) who have received at least one prior therapy (relapsed/refractory population) or who are… | Jul 2021 | Not recommended | 15 individuals Lymphoma Foundation · Leukaemia Foundation · Rare Cancers Australia |
Who spoke
Lymphoma Foundation · Leukaemia Foundation · Rare Cancers Australia
What the PBS pays
$136M in government benefit over 2024–25, across 17,241 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| zanubrutinib | $136.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| zanubrutinibZanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | recommended restricted | 2022-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.